Psoriasis Induced by Biological Therapy
Por:
Montolio Chiva L, Martínez Ferrer À, Mateu Puchades A, Campos Fernández C, Narváez Garcia J and Alegre Sancho JJ
Publicada:
1 oct 2021
Ahead of Print:
1 sep 2021
Categoría:
Rheumatology
Resumen:
Objective: To describe a multicentre case series of new onset or worsening of psoriasis in patients treated with biological drugs.
Material and methods: Descriptive study. We reviewed the clinical history of patients with chronic inflammatory disease (CID) treated with biological drugs, who developed new onset or worsening of psoriasis during the follow-up period.
Results: Twenty-six cases of paradoxical psoriasis (PP) were recorded. Ninety-three percent of the patients were treated with anti-TNFot and adalimumab was responsible for 50% of the cases. Only 5 patients had a personal history of psoriasis. The biological drug was discontinued in 13 patients. Lesion recurrence was more frequent when another anti-TNFot was reintroduced.
Conclusions: The PP is a reversible adverse effect that can be observed in patients exposed to biological drugs, mainly anti-TNFot. (C) 2020 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
Filiaciones:
:
Servicio de Reumatología, Hospital Universitario Doctor Peset, Valencia, España
:
Servicio de Reumatología, Hospital Universitario Doctor Peset, Valencia, España
:
Servicio de Dermatología, Hospital Universitario Doctor Peset, Valencia, España
Campos Fernández C:
Servicio de Reumatología y Metabolismo óseo, Consorcio Hospital General Universitario, Valencia, España
Narváez Garcia J:
Servicio de Reumatología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España
:
Servicio de Reumatología, Hospital Universitario Doctor Peset, Valencia, España
Open Access
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version. |
| No Accesible |
|